182 related articles for article (PubMed ID: 24215357)
1. A wogonin-loaded glycyrrhetinic acid-modified liposome for hepatic targeting with anti-tumor effects.
Tian J; Wang L; Wang L; Ke X
Drug Deliv; 2014 Nov; 21(7):553-9. PubMed ID: 24215357
[TBL] [Abstract][Full Text] [Related]
2. The anti-tumor performance of docetaxel liposomes surface-modified with glycyrrhetinic acid.
Li J; Xu H; Ke X; Tian J
J Drug Target; 2012 Jun; 20(5):467-73. PubMed ID: 22577855
[TBL] [Abstract][Full Text] [Related]
3. Doxorubicin-loaded glycyrrhetinic acid modified recombinant human serum albumin nanoparticles for targeting liver tumor chemotherapy.
Qi WW; Yu HY; Guo H; Lou J; Wang ZM; Liu P; Sapin-Minet A; Maincent P; Hong XC; Hu XM; Xiao YL
Mol Pharm; 2015 Mar; 12(3):675-83. PubMed ID: 25584860
[TBL] [Abstract][Full Text] [Related]
4. Development of Salvianolic acid B-Tanshinone II A-Glycyrrhetinic acid compound liposomes: formulation optimization and its effects on proliferation of hepatic stellate cells.
Lin J; Wang X; Wu Q; Dai J; Guan H; Cao W; He L; Wang Y
Int J Pharm; 2014 Feb; 462(1-2):11-8. PubMed ID: 24374609
[TBL] [Abstract][Full Text] [Related]
5. Cellular uptake mechanism and clearance kinetics of fluorescence-labeled glycyrrhetinic acid and glycyrrhetinic acid-modified liposome in hepatocellular carcinoma cells.
Sun Y; Lu J; Yan D; Shen L; Hu H; Chen D
Environ Toxicol Pharmacol; 2017 Jul; 53():46-56. PubMed ID: 28501784
[TBL] [Abstract][Full Text] [Related]
6. Glycyrrhetinic Acid and TAT Peptide Modified Dual-functional Liposomes for Treatment of Hepatocellular Cancer.
Huang S; Ren D; Wu X; Li M; Yu X; Nie X; Wang Y; Wang Y
Curr Top Med Chem; 2020; 20(27):2493-2505. PubMed ID: 32703132
[TBL] [Abstract][Full Text] [Related]
7. Antitumor activities of novel glycyrrhetinic acid-modified curcumin-loaded cationic liposomes in vitro and in H22 tumor-bearing mice.
Chang M; Wu M; Li H
Drug Deliv; 2018 Nov; 25(1):1984-1995. PubMed ID: 30499350
[TBL] [Abstract][Full Text] [Related]
8. Dual-Ligand-Functionalized Liposomes Based on Glycyrrhetinic Acid and cRGD for Hepatocellular Carcinoma Targeting and Therapy.
Qiu M; Wang J; Bai J; Li X; Tian C; Liu Z; Zheng C; Clark AR; Cheng X; Liao X; Wu S; Lee RJ; Zhou X
Mol Pharm; 2023 Apr; 20(4):1951-1963. PubMed ID: 36952242
[TBL] [Abstract][Full Text] [Related]
9. [Preparation of liposomes surface-modified with glycyrrhetinic acid targeting to hepatocytes].
Mao SJ; Hou SX; Jin H; Zhang LK; Jiang-Bin
Zhongguo Zhong Yao Za Zhi; 2003 Apr; 28(4):328-31. PubMed ID: 15139140
[TBL] [Abstract][Full Text] [Related]
10. Development of 11-DGA-3-
Zhou L; Zou M; Zhu K; Ning S; Xia X
Molecules; 2019 Aug; 24(17):. PubMed ID: 31450608
[TBL] [Abstract][Full Text] [Related]
11. 18-GA-Suc Modified Liposome Loading Cantharidin for Augmenting Hepatic Specificity: Preparation, Characterization, Antitumor Effects, and Liver-Targeting Efficiency.
Zhu K; Zhou L; Zou M; Ning S; Liu S; Zhou Y; Du K; Zhang X; Xia X
J Pharm Sci; 2020 Jun; 109(6):2038-2047. PubMed ID: 32173319
[TBL] [Abstract][Full Text] [Related]
12. Hepatocellular carcinoma-targeted effect of configurations and groups of glycyrrhetinic acid by evaluation of its derivative-modified liposomes.
Sun Y; Dai C; Yin M; Lu J; Hu H; Chen D
Int J Nanomedicine; 2018; 13():1621-1632. PubMed ID: 29588589
[TBL] [Abstract][Full Text] [Related]
13. Enhanced distribution and extended elimination of glycyrrhetinic acid in mice liver by mPEG-PLA modified (mPEGylated) liposome.
Li J; Yu H; Li S; Wang GJ
J Pharm Biomed Anal; 2010 Apr; 51(5):1147-53. PubMed ID: 20005656
[TBL] [Abstract][Full Text] [Related]
14. Glycyrrhetinic acid-graft-hyaluronic acid conjugate as a carrier for synergistic targeted delivery of antitumor drugs.
Zhang L; Yao J; Zhou J; Wang T; Zhang Q
Int J Pharm; 2013 Jan; 441(1-2):654-64. PubMed ID: 23117024
[TBL] [Abstract][Full Text] [Related]
15. HPLC assay and pharmacokinetics and tissue distribution study of glycyrrhetinic acid liposomes modified with galactosylated lipid.
Guo BH; Cheng Y; Wu W; Lin LP; Lin DH
J Liposome Res; 2012 Jun; 22(2):120-7. PubMed ID: 22313057
[TBL] [Abstract][Full Text] [Related]
16. Enhanced targeted delivery of adenine to hepatocellular carcinoma using glycyrrhetinic acid-functionalized nanoparticles in vivo and in vitro.
Wu F; Xue H; Li X; Diao W; Jiang B; Wang W; Yu W; Bai J; Wang Y; Lian B; Feng W; Sun T; Qu M; Zhao C; Wang Y; Wu J; Gao Z
Biomed Pharmacother; 2020 Nov; 131():110682. PubMed ID: 32947204
[TBL] [Abstract][Full Text] [Related]
17. Glycyrrhetinic Acid Mediated Drug Delivery Carriers for Hepatocellular Carcinoma Therapy.
Cai Y; Xu Y; Chan HF; Fang X; He C; Chen M
Mol Pharm; 2016 Mar; 13(3):699-709. PubMed ID: 26808002
[TBL] [Abstract][Full Text] [Related]
18. Development of glycyrrhetinic acid-modified stealth cationic liposomes for gene delivery.
He ZY; Zheng X; Wu XH; Song XR; He G; Wu WF; Yu S; Mao SJ; Wei YQ
Int J Pharm; 2010 Sep; 397(1-2):147-54. PubMed ID: 20667672
[TBL] [Abstract][Full Text] [Related]
19. [Liver targeting of compound liposomes mediated by glycyrrhetinic acid derivative receptor and its effect on hepatic stellate cells].
Wang XL; Guan HD; Qu SX; Xue BW; Li G; Liu XY; Chen LS; Gu H
Zhongguo Zhong Yao Za Zhi; 2023 Oct; 48(19):5195-5204. PubMed ID: 38114109
[TBL] [Abstract][Full Text] [Related]
20. Anti-hepatitis B virus activity of wogonin in vitro and in vivo.
Guo Q; Zhao L; You Q; Yang Y; Gu H; Song G; Lu N; Xin J
Antiviral Res; 2007 Apr; 74(1):16-24. PubMed ID: 17280723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
